The intriguing options of multispecific antibody formats for treatment of cancer

Cancer Genomics and Proteomics

Volumn 10, Issue 1, 2013, Pages 1-18

  Weidle, Ulrich H ^a   Tiefenthaler, Georg ^a   Weiss, Elisabeth H ^b   Georges, Guy ^a   Brinkmann, Ulrich ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody formats; Cytokine delivery; Death receptors; HER signaling; Inhibition of angiogenesis; Recruitment of immune effector cells; Review.

Indexed keywords

ANTINEOPLASTIC AGENT; CD28 ANTIGEN; CYTOKINE; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; MM 111; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; B LYMPHOCYTE; CANCER CELL; CANCER THERAPY; CYTOTOXICITY; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 84875032564     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Walsh G: Biopharmaceutical benchmarks 2010. Nat Biotechnol 28: 917-924, 2010.
2. Weiner LM, Surana R and Wang S: Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327, 2010.
3. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157, 2005.
4. Khalil M and Vonderheide RH: Anti-CD40 agonist antibodies: Preclinical and clinical experience. Update Cancer Ther 2: 61-65, 2007.
5. Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996.
6. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
7. Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30: 1073-1081, 2009.
8. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
9. Garrett JT and Arteaga CL: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 11: 793-800, 2011.
10. Coloma MJ and Morrison SL: Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15: 159-163, 1997.
11. Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, Lammens A, Scheuer W, Hoffmann E, Mundigl O and Brinkmann U: Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 108: 8194-8199, 2011.
12. Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, Scher W, Ji C, Heilek G, Cammack N, Brandt M, Umana P and Brinkmann U: Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 55: 2369-2378, 2011.
13. Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P and Klein C: Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 526: 206-218, 2012.
14. Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, Niederfellner G and Sustmann C: Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel 25: 551-560, 2012.
15. Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, Fang C, Zheng L, Zhang X, Liang P, Zhang X, Li B and Guo Y: A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett 299: 130-136, 2010.
16. Kontermann RE: Alternative antibody formats. Curr Opin Mol Ther 12: 176-183, 2010.
17. Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C and Brinkmann U: Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 25: 571-580, 2012.
18. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G and Eigenbrot C: A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20: 472-486, 2011.
19. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C and Fuh G: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen-binding site. Science 323: 1610-1614, 2009.
20. Ridgway JB, Presta LG and Carter P: 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9: 617-621, 1996.
21. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM and Huston JS: SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 23: 195-202, 2010.
22. Munda M, Gross AW, Dawson JP, He C, Kursosawa E, Scheickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, Wesolowski JS, Kelton C, Neuteboom B and Hock B: Therapeutic assessment of SEED: A new engineered antibody platform designed to generate mono-and bispecific antibodies. Protein Eng Des Sel 24: 447-454, 2011.
23. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG and Carter P: An efficient route to human bispecific IgG. Nat Biotechnol 16: 677-681, 1998.
24. Schaefer W, Regula JT, Bner M, Schanzer J, Croasdale R, Dr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W and Klein C: Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108: 11187-11192, 2011.
25. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT and Schaefer W: Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 4: 653-664, 2012.
26. Weiner LM, Murray JC and Shuptrine CW: Antibody-based immunotherapy of cancer. Cell 148: 1081-1084, 2012.
27. Stork R, Mler D and Kontermann RE: A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 20: 569-576, 2007.
28. Mler D, Karle A, Meissburger B, Hig I, Stork R and Kontermann RE: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 282: 12650-12660, 2007.
29. Chapman AP: PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 54: 531-545, 2002.
30. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA and Kufer P: T-Cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA 107: 12605-12610, 2010.
31. Kipriyanov SM, Moldenhauer G, Schumacher J, Cochlovius B, Von der Lieth CW, Matys ER and Little M: Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293: 41-56, 1999.
32. Korn T, Nettelbeck DM, Vkel T, Mler R and Kontermann RE: Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: A comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6: 642-651, 2004.
33. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E and Johnson S: Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117: 4542-4551, 2011.
34. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM and Chang CH: Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 103: 6841-6846, 2006.
35. Kufer P, Lutterbe R and Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 22: 238-244, 2004.
36. Fischer N and Ler O: Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74: 3-14, 2007.
37. Tacke M, Hanke G, Hanke T and Hig T: CD28-mediated induction of proliferation in resting T-cells in vitro and in vivo without engagement of the T-cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol 27: 239-247, 1997.
38. Otz T, Grosse-Hovest L, Hofmann M, Rammensee HG and Jung G: A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 23: 71-77, 2009.
39. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG and Jung G: A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 33: 1334-1340, 2003.
40. Grosse-Hovest L, Mler S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, Lassnig C, Besenfelder U, Mler M, Lytton SD, Jung G and Brem G: Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 101: 6858-6863, 2004.
41. Grosse-Hovest L, Wick W, Minoia R, Weller M, Rammensee HG, Brem G and Jung G: Supra agonistic, bispecific singlechain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 117: 1060-1064, 2005.
42. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD and Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028, 2006.
43. Lindhofer H, Mocikat R, Steipe B and Thierfelder S: Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155: 219-225, 1995.
44. Zeidler R, Mysliwietz J, Csady M, Walz A, Ziegler I, Schmitt B, Wollenberg B and Lindhofer H: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83: 261-266, 2000.
45. Heiss MM, Strlein MA, Jer M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW and Lindhofer H: Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117: 435-443, 2005.
46. Jer M, Schoberth A, Ruf P, Hess J and Lindhofer H: The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 69: 4270-4276, 2009.
47. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schrer P and Lindhofer H: Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 123: 1181-1189, 2008.
48. Ruf P, Jer M, Ellwart J, Wosch S, Kusterer E and Lindhofer H: Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer 108: 725-732, 2004.
49. Ruf P and Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526-2534, 2001.
50. Burges A, Wimberger P, Kper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jer M, Strlein MA, Heiss MM, Gottwald T, Lindhofer H and Kimmig R: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM anti-CD3 antibody: A phase I/II study. Clin Cancer Res 13: 3899-3905, 2007.
51. Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D, Lindhofer H and Kolb HJ: Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 43: 383-397, 2009.
52. Baeuerle PA, Kufer P and Bargou R: BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11: 22-30, 2009.
53. Wolf E, Hofmeister R, Kufer P, Schlereth B and Baeuerle PA: BiTEs: Bispecific antibody constructs with unique antitumor activity. Drug Discov Today 10: 1237-1244, 2005.
54. Baeuerle PA and Reinhardt C: Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69: 4941-4944, 2009.
55. Mack M, Riethmler G and Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92: 7021-7025, 1995.
56. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmler G, Bargou R and Baeuerle PA: Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100: 690-697, 2002.
57. Offner S, Hofmeister R, Romaniuk A, Kufer P and Baeuerle PA: Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43: 763-771, 2006. 58 Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N and Baeuerle PA: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115: 98-104, 2005.
58. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbe R, Schlereth B, Kufer P and Baeuerle PA: Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214: 441-453, 2009.
59. MhA; M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R and Baeuerle PA: CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 44: 1935-1943, 2007.
60. Dreier T, Baeuerle PA, Fichtner I, Gr M, Schlereth B, Lorenczewski G, Kufer P, Lutterbe R, Riethmler G, Gjorstrup P and Bargou RC: T-Cell co-stimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B-cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 170: 4397-4402, 2003.
61. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R and Baeuerle PA: Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65: 2882-2889, 2005.
62. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K and Baeuerle PA: T-Cell activation and Bcell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 55: 503-514, 2006.
63. Lfler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dken B and Bargou RC: Efficient elimination of chronic lymphocytic leukaemia B-cells by autologous T-cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17: 900-909, 2003.
64. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmler G, Reinhardt C, Baeuerle PA and Kufer P: Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 321: 974-977, 2008.
65. McAleese F and Eser M: RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol 8: 687-695, 2012.
66. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G and Little M: Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 CD19 tandem diabody, and CD28 costimulation. Cancer Res 60: 4336-4341, 2000.
67. Gupta P, Goldenberg DM, Rossi EA and Chang CH: Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 116: 3258-3267, 2010.
68. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR and Chang CH: Dual-targeting immunotherapy of lymphoma: Potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 119: 3767-3778, 2012.
69. Kuo SR, Wong L and Liu JS: Engineering a CD123CD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel 25: 561-569, 2012 71 Bowles JA and Weiner GJ: CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304: 88-99, 2005.
70. Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY and Lazar GA: A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 3: 546-557, 2011.
71. Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, Solomon A and Saito S: A novel membrane antigen selectively expressed on terminally differentiated human B-cells. Blood 84: 1922-1930, 1994.
72. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, Wehner R, Schmitz M, Bornhser M, von Bonin M, Ehninger G, Bartsch H and Bachmann M: Generation of singlechain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T-cell synapses. Anal Biochem 423: 261-268, 2012.
73. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B and Fey GH: A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemia cells. J Immunother 31: 871-884, 2008.
74. Kler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A and Fey GH: A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 150: 574-86, 2010.
75. Schubert I, Kellner C, Stein C, Kler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, Mackensen A and Fey GH: A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 3: 21-30, 2011.
76. Schubert I, Kellner C, Stein C, Kler M, Schwenkert M, Saul D, Stockmeyer B, Berens C, Oduncu FS, Mackensen A and Fey GH: A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen doublepositive cells by dual-targeting. MAbs 4: 45-56, 2012.
77. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr. and Shepard HM: Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985.
78. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
79. Rgg C, Yilmaz A, Bieler G, Bamat J, Chaubert P and Lejeune FJ: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408-414, 1998. 82 Robert B, Mach JP, Mani JC, Ychou M, Folli S, Artus JC and Pelegrin A: Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res 56: 4758-4765, 1996.
80. Zimmerman RJ, Chan A and Leadon SA: Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 49: 1644-1648, 1989.
81. Azria D, Larbouret C, Garambois V, Kramar A, Martineau P, Robert B, Ailles N, Ychou M, Dubois JB and Pegrin A: Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer. Br J Cancer 89: 1987-1994, 2003.
82. Larbouret C, Robert B, Linard C, Teulon I, Gourgou S, Bibeau F, Martineau P, Santoro L, Pouget JP, Pelegrin A and Azria D: Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int J Radiat Oncol Biol Phys 69: 1231-1237, 2007.
83. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809, 1993.
84. Jung G, Grosse-Hovest L, Krammer PH and Rammensee HG: Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 61: 1846-1848, 2001.
85. Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG and Jung G: Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 68: 1221-1227, 2008.
86. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J and Glaser SM: Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. MAbs 1: 128-141, 2009.
87. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS and Glaser SM: Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 23: 549-57, 2010.
88. Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, Glaser SM, Croner LJ and Demarest SJ: Conserved amino acid networks involved in antibody variable domain interactions. Proteins 76: 99-114, 2009.
89. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
90. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
91. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX and Stern HM: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68: 5878-5887, 2008.
92. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd and Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933-8938, 2003.
93. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B and Nielsen UB: Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11: 582-593, 2012.
94. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD and Adams GP: Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 99: 1415-1425, 2008.
95. Holliger P and Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136, 2005.
96. Jones RB, Gordus A, Krall JA and MacBeath G: A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439: 168-174, 2006.
97. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
98. Lundberg E, Brismar H and Grlund T: Selection and characterization of Affibody ligands to the transcription factor c-Jun. Biotechnol Appl Biochem 52: 17-27, 2009.
99. Nilsson B, Moks T, Jansson B, Abrahms L, Elmblad A, Holmgren E, Henrichson C, Jones TA and Uhl M: A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1: 107-113, 1987.
100. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L and Zhu Z: Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279: 2856-2865, 2004.
101. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L and Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280: 19665-19672, 2005.
102. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, BergY, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L and Tabernero J: Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 29: 3783-3790, 2011.
103. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M and Pao W: High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4, 2009, e7273
104. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD and Gore L: A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465, 2010.
105. Chen W, Feng Y, Zhao Q, Zhu Z and Dimitrov DS: Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics. Mol Cancer Ther 11: 1400-1410, 2012. 109 Childs SG: The pathogenesis of systemic lupus erythematosus. Orthop Nurs 25: 140-145, 2006.
106. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
107. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
108. Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L and Zhu Z: Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, FMS-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 61: 7002-7008, 2001.
109. Denhardt DT and Guo X: Osteopontin: A protein with diverse functions. FASEB J 7: 1475-1482, 1993.
110. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W and Guo Y: Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28: 3412-3422, 2009.
111. Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, Fang C, Zheng L, Zhang X, Liang P, Zhang X, Li B and Guo Y: A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett 299: 130-136, 2010.
112. Ostman A: PDGF receptors mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15: 275-286, 2004.
113. Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL and Zhu Z: An antibody directed against PDGF receptor beta enhances the antitumor and the antiangiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357: 1142-1147, 2007.
114. Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H and Zhu Z: Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 281: 10706-10714, 2006.
115. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L and Zhu Z: Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11: 594-604, 2009.
116. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV and Snavely M: A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates antiangiogenic activity in vitro and in vivo. MAbs 2: 20-34, 2010.
117. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim NK, Jeon CJ, Lee GM, Jeon BH, Nam DH, Sung HK, Nagy A, Yoo OJ and Koh GY: Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171-184, 2010.
118. Reichlin M, Martin A, Taylor-Albert E, Tsuzaka K, Zhang W, Reichlin MW, Koren E, Ebling FM, Tsao B and Hahn BH: Lupus autoantibodies to native DNA cross-react with the A and D SnRNP polypeptides. J Clin Invest 93: 443-449, 1994.
119. Zack DJ, Stempniak M, Wong AL, Taylor C and Weisbart RH: Mechanisms of cellular penetration and nuclear localization of an anti-double-strand DNA autoantibody. J Immunol 157: 2082-2088, 1996.
120. Weisbart RH, Stempniak M, Harris S, Zack DJ and Ferreri K: An autoantibody is modified for use as a delivery system to target the cell nucleus: Therapeutic implications. J Autoimmun 11: 539-546, 1998.
121. Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH and Reeves ME: Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res 67: 1769-1774, 2007.
122. Heinze E, Baldwin S, Chan G, Hansen J, Song J, Clements D, Aragon R, Nishimura R, Reeves M and Weisbart R. Antibodymediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. Int J Oncol 35: 167-173, 2009.
123. Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureil C, Teillaud JL, Tocque B and Bracco L: Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18: 551-557, 1999.
124. Weisbart RH, Wakelin R, Chan G, Miller CW and Koeffler PH: Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int J Oncol 25: 1113-1118, 2004.
125. Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31, 2007.
126. Lane DP, Brown CJ, Verma C and Cheok CF: New insights into p53-based therapy. Discov Med 12: 107-117, 2011.
127. Weisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ and Nishimura RN: A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets. Mol Cancer Ther 11: 2169-2173, 2012.
128. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.
129. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM and Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7: 95-106, 2007.
130. Wst T, Moosmayer D and Pfizenmaier K: Construction of a bispecific single chain antibody for recruitment of cytotoxic Tcells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol 92: 159-168, 2001.
131. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The Protein Data Bank. Nucleic Acids Res 28: 235-242, 2000.
132. Accelrys Software Inc., Discovery Studio Modeling Environment, Release 3.1 . San Diego: Accelrys Software Inc., 2007.